HomeCompareFGPHF vs PFE

FGPHF vs PFE: Dividend Comparison 2026

FGPHF yields 4264.39% · PFE yields 6.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 FGPHF wins by $13311240675884.28M in total portfolio value
10 years
FGPHF
FGPHF
● Live price
4264.39%
Share price
$0.05
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$13311240675884.33M
Annual income
$12,724,273,753,464,259,000.00
Full FGPHF calculator →
PFE
Pfizer Inc.
● Live price
6.13%
Share price
$28.08
Annual div
$1.72
5Y div CAGR
13.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$49.6K
Annual income
$26,258.71
Full PFE calculator →

Portfolio growth — FGPHF vs PFE

📍 FGPHF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodFGPHFPFE
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, FGPHF + PFE cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
FGPHF pays
PFE pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

FGPHF
Annual income on $10K today (after 15% tax)
$362,473.35/yr
After 10yr DRIP, annual income (after tax)
$10,815,632,690,444,620,000.00/yr
PFE
Annual income on $10K today (after 15% tax)
$520.66/yr
After 10yr DRIP, annual income (after tax)
$22,319.90/yr
At 15% tax rate, FGPHF beats the other by $10,815,632,690,444,597,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of FGPHF + PFE for your $10,000?

FGPHF: 50%PFE: 50%
100% PFE50/50100% FGPHF
Portfolio after 10yr
$6655620337942.19M
Annual income
$6,362,136,876,732,143,000.00/yr
Blended yield
95.59%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PFE right now

FGPHF
No analyst data
Altman Z
17.8
Piotroski
2/9
PFE
Analyst Ratings
16
Buy
22
Hold
1
Sell
Consensus: Hold
Price Target
$27.50
-2.1% upside vs current
Range: $24.00 — $35.00
Altman Z
2.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

FGPHF buys
0
PFE buys
0
No recent congressional trades found for FGPHF or PFE in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricFGPHFPFE
Forward yield4264.39%6.13%
Annual dividend / share$2.00$1.72
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%13.2%
Portfolio after 10y$13311240675884.33M$49.6K
Annual income after 10y$12,724,273,753,464,259,000.00$26,258.71
Total dividends collected$13271302165952.95M$58.3K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: FGPHF vs PFE ($10,000, DRIP)

YearFGPHF PortfolioFGPHF Income/yrPFE PortfolioPFE Income/yrGap
1← crossover$437,139$426,439.23$9,153$693.39+$428.0KFGPHF
2$17,889,544$17,421,805.49$8,593$849.25+$17.88MFGPHF
3$685,471,065$666,329,252.39$8,336$1,066.78+$685.46MFGPHF
4$24,594,800,522$23,861,346,482.18$8,437$1,384.80+$24594.79MFGPHF
5$826,455,266,378$800,138,829,819.73$9,013$1,875.40+$826455.26MFGPHF
6$26,012,289,347,774$25,127,982,212,749.59$10,306$2,680.72+$26012289.34MFGPHF
7$766,983,969,668,400$739,150,820,066,281.60$12,820$4,101.38+$766983969.66MFGPHF
8$21,189,076,648,850,730$20,368,403,801,305,540.00$17,673$6,826.70+$21189076648.83MFGPHF
9$548,567,217,215,019,650$525,894,905,200,749,440.00$27,543$12,591.86+$548567217214.99MFGPHF
10$13,311,240,675,884,329,000$12,724,273,753,464,259,000.00$49,560$26,258.71+$13311240675884.28MFGPHF

FGPHF vs PFE: Complete Analysis 2026

FGPHFStock

First Graphene Limited engages in the research, development, mining, exploration, manufacture, and sale of graphene products in Australia. It operates through Graphene Production, Research and Development, and Mining Asset Maintenance segments. The company offers MB-LDPE graphene enhanced masterbatch, MB-EVA graphene enhanced masterbatch, MB-EVA bitumen graphene enhanced masterbatch, aqua pre-dispersed graphene additives, and nanoplatelet additives under the PureGRAPH brand. The company also develops and sells VFD, TTF, and other 2D devices and materials. Its products are used in the coating and inks, composite, elastomer, fire retardancy, concrete, textile, and energy storage applications. First Graphene Limited is headquartered in Henderson, Australia.

Full FGPHF Calculator →

PFEHealthcare

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Full PFE Calculator →
📬

Get this FGPHF vs PFE comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

FGPHF vs SCHDFGPHF vs JEPIFGPHF vs OFGPHF vs KOFGPHF vs MAINFGPHF vs JNJFGPHF vs MRKFGPHF vs ABBV

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.